RESEARCH TRIANGLE PARK, NORTH CAROLINA, May 04, 2026
BioCryst Pharmaceuticals has announced a strategic European licensing agreement with an Irish affiliate of Neopharmed Gentili for navenibart, an investigational long-acting plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). Under the agreement, Neopharmed Gentili receives exclusive commercialization rights in Europe, while BioCryst secures a $70 million upfront payment, with potential milestone payments of up to $275 million and tiered royalties ranging from 18% to 30% on net sales. This collaboration marks a significant expansion of both companies’ efforts to advance innovative therapies in rare diseases, reinforcing their commitment to improving patient outcomes across global markets.
Strategic Licensing Strengthens Rare Disease Portfolio
The agreement builds upon an existing partnership between BioCryst and Neopharmed Gentili, following the previous transfer of the European ORLADEYO® business in 2025, and reflects a long-term strategic alignment in hereditary angioedema treatment. By leveraging Neopharmed Gentili’s established commercial infrastructure in Europe, BioCryst aims to ensure efficient market access, streamlined distribution, and strong execution continuity.
This approach enables BioCryst to focus on U.S. commercialization and pipeline expansion, while benefiting from regional expertise and operational efficiency in Europe. The deal also enhances BioCryst’s financial position, providing immediate capital to support ongoing research and development activities while maintaining long-term revenue potential through milestone payments and royalties.
Navenibart Advances as Next-Generation HAE Therapy
Advertisement
Navenibart is currently in a Phase 3 clinical development program, with plans to support U.S. regulatory filing by the end of 2027, positioning it as a potential next-generation therapy for hereditary angioedema, a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes. As a plasma kallikrein inhibitor, navenibart is designed to prevent excessive bradykinin production, the key driver of HAE attacks, offering a targeted mechanism of action.
Its long-acting profile may provide advantages in reducing dosing frequency and improving patient adherence, addressing key limitations of existing therapies. The ongoing clinical program reflects a broader industry focus on innovative biologics and precision therapies aimed at delivering more effective and convenient treatment options for rare disease patients.
Expanding Global Access and Regulatory Pathways
The collaboration highlights the growing importance of global licensing agreements in accelerating drug development and commercialization, particularly in the rare disease sector, where patient populations are limited and require specialized market strategies.
From a GxP perspective, the continued development of navenibart will adhere to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards, ensuring data integrity, product quality, and regulatory compliance across all stages of development.
The agreement also supports enhanced patient access to innovative therapies, as Neopharmed Gentili’s regional expertise is expected to facilitate faster regulatory approvals and broader market penetration in Europe. As the demand for advanced HAE treatments continues to grow, this partnership positions both companies to drive innovation, improve clinical outcomes, and expand global access to life-changing therapies, reinforcing their leadership in the biopharmaceutical rare disease landscape.
Source: BioCryst Pharmaceuticals, Neopharmed Gentili press release
